CervoMed Announces Private Placement With Expected Gross Proceeds Of ~$10.5M; Will Extend Cash Runway Into Q2 2027

CervoMed Inc.

CervoMed Inc.

CRVO

0.00

Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies

Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial

Financing includes substantial participation from insiders and leading institutional healthcare investors

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.